Correspondence 0001104659-24-008273 from Evaxion A/S (EVAX)
Evaxion A/S
Date: Jan. 30, 2024 · CIK: 0001828253 · Accession: 0001104659-24-008273
AI Filing Summary & Sentiment
File numbers found in text: 333-276505
Letter
Office of Life Sciences Division of Corporation Finance Registration Statement on Form F-1 (File No. 333-276505) Acceleration Request Requested Date: January 31, 2024 Requested Time: 5:15 P.M. Eastern Time
Dear Mr. Campbell:
In accordance with Rule 461 of Regulation C of the General Rules and Regulations under the Securities Act of 1933, as amended, the undersigned registrant (the “Registrant”) hereby requests that the Securities and Exchange Commission (the “Commission”) take appropriate action to cause the above-referenced Registration Statement on Form F-1 (File No. 333-276505) (the “Registration Statement”) to become effective on Wednesday, January 31, 2024, at 5:15 p.m., Eastern Time, or as soon thereafter as practicable, or at such later time as the Registrant or its counsel may orally request via telephone call to the staff (the “Staff”).
Once the Registration Statement has been declared effective, please orally confirm that event with Michael D. Baird of Duane Morris LLP by telephone at (215) 870-6771, or in his absence you can also contact Dwight A. Kinsey of Duane Morris LLP by telephone at (917) 620-3675, or if you have any questions or require additional information regarding this matter. Thank you for your assistance and cooperation in this matter.
The Company understands that the Staff will consider this request as confirmation by the Company of its awareness of its responsibilities under the federal securities laws as they relate to the offering of the securities covered by the Registration Statement.
Very truly yours,
Evaxion Biotech A/S
Show Raw Text
CORRESP
1
filename1.htm
Evaxion Biotech A/S
Dr. Neergaards
Vej 5F
2970 Hørsholm
Denmark
Telephone: +45 31 31
97 53
January 30, 2024
U.S. Securities and Exchange Commission
Office of Life Sciences
Division of Corporation Finance
100 F Street, N.E.
Mail Stop 4546
Washington, D.C. 20549
Attn:
Mr. Alan Campbell
Re: Evaxion Biotech A/S
Registration Statement on Form F-1 (File No. 333-276505)
Acceleration Request
Requested Date: January 31, 2024
Requested Time: 5:15 P.M. Eastern Time
Dear Mr. Campbell:
In accordance with Rule 461 of Regulation C of
the General Rules and Regulations under the Securities Act of 1933, as amended, the undersigned registrant (the “Registrant”)
hereby requests that the Securities and Exchange Commission (the “Commission”) take appropriate action to cause
the above-referenced Registration Statement on Form F-1 (File No. 333-276505) (the “Registration Statement”)
to become effective on Wednesday, January 31, 2024, at 5:15 p.m., Eastern Time, or as soon thereafter as practicable, or at such later
time as the Registrant or its counsel may orally request via telephone call to the staff (the “Staff”).
Once the Registration Statement has been
declared effective, please orally confirm that event with Michael D. Baird of Duane Morris LLP by telephone at (215) 870-6771, or in
his absence you can also contact Dwight A. Kinsey of Duane Morris LLP by telephone at (917) 620-3675, or if you have any questions
or require additional information regarding this matter. Thank you for your assistance and cooperation in this matter.
The Company understands that the Staff will
consider this request as confirmation by the Company of its awareness of its responsibilities under the federal securities laws as they
relate to the offering of the securities covered by the Registration Statement.
Very truly yours,
Evaxion Biotech A/S
By:
/s/ Christian Kanstrup
Christian Kanstrup
Chief Executive Officer
cc:
Dwight A. Kinsey, Duane Morris LLP
Michael D. Baird, Duane Morris LLP
Lars Lüthjohan Jensen, Mazanati-Andersen
2